The Proteasome Activator PA28γ and P53: It Takes Two to Tango, but Which One Takes the Lead?


The phosphoprotein p53 was trivially named after the apparent molecular mass it runs on SDS-PAGE, i.e., 53-kilodalton (kDa). Ever since its discovery in 1979 by several groups simultaneously, this extraordinary protein has captured the imagination of life scientists. p53 is likely the most extensively studied protein in cell biological research. To underscore its importance, p53 has been called a “cellular gatekeeper” [1] or “the guardian of the genome” [2], and for a long time researchers believed that p53 was the universal master switch that defined cancer onset and progression. However, this turned out to be not entirely true. Nonetheless, at least half of all cancer types carry aberrations in the p53 gene (TP53). p53 acts as a decision nodule that organizes the cell’s response to stress. Continue reading

Conference Exhibitions and Sponsorships in 2014

Conference Exhibitions and Sponsorships in 2014

MDPI journals and staff will be present and/or sponsor several academic events in 2014. Here is a current selection (we will update this list from time to time to include more).

If you are organizing a conference related to a topic covered by one of our journals, please suggest your event for our consideration at, or get in touch with Alexander Thiesen ( Continue reading

HCMV Vaccine Development Targets Immunomodulatory Proteins

Guest Commentary by Anamaris Colberg-Poley*


Human cytomegalovirus (HCMV) can cause severe disease in immunocompromised individuals and in congenitally infected infants, thus the development of an HCMV vaccine has been a national priority over the last few decades.  Despite attempts similar to those which have proven successful for other herpesviruses, such as varicella zoster virus, attenuated HCMV vaccine strains (such as Towne) have not been analogously successful as effective HCMV vaccines. Continue reading